A Study of Novel Study Interventions and Combinations in Participants with Colorectal Cancer - CANTOR

Study identifier:D798VC00001

ClinicalTrials.gov identifier:NCT06792695

EudraCT identifier:N/A

CTIS identifier:2024-518469-84-00

Will Be Recruiting

Official Title

A Phase II, Open-label, Multicenter, Master Protocol to Evaluate the Safety and Efficacy of Novel Study Interventions and Combinations in Participants with Colorectal Cancer (CANTOR)

Medical condition

Metastatic Colorectal Cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab

Sex

All

Estimated Enrollment

120

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 19 Mar 2025
Estimated Primary Completion Date: 31 Mar 2027
Estimated Study Completion Date: 19 Jan 2028

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2025 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria